Sudhin Biopharma Co

Supplier
Summarized by Halo AI

Sudhin Biopharma Co. is a biotechnology company that develops novel, patented BioSettler technology for efficient, continuous cell retention, clarification, and concentration in biopharmaceutical manufacturing and cell therapy applications.

Company size
Less than 500 employees
Portfolio summary
Inclined, compact, and single-use plastic BioSettler cell retention devices, perfusion bioreactor systems, and recombinant proteins produced via yeast-based precision fermentation, including Brazzein sweet proteins and human albumin
Markets served
NA · APAC
Manufacturing locations
A precision fermentation production site in Chennai, India, operated via its subsidiary, Sudhin Biotech Private Limited
R&D locations
Superior, CO · Chennai, India

Sudhin Biopharma Co. is a biotechnology company that develops advanced manufacturing technologies for the biopharmaceutical and cell therapy industries. Their core technology, the BioSettler, is a patented device designed for the efficient, continuous separation and retention of cells in bioprocessing applications. Utilizing inclined or conical settling surfaces, these compact devices enable selective cell retention in perfusion bioreactors, which helps maintain high cell densities and viability. The company offers these settlers in various sizes, ranging from laboratory-scale modules to larger, customizable units, including single-use disposable plastic versions, to facilitate tasks such as cell culture clarification, harvesting, washing, and the concentration of therapeutic biologicals like antibodies, viral vectors, and cell therapy products.

These solutions are designed to address the challenges of traditional biological manufacturing by improving process efficiency and productivity. By providing modular devices that can be integrated into existing bioreactor setups, Sudhin Biopharma assists manufacturers in various sectors, including the production of therapeutic biologics, stem cells, organoids, and viral vaccines. The technology has been demonstrated for applications in both mammalian and microbial cell culture, helping to reduce processing times and improve the yield of secreted products. Through collaborations and grant-funded projects, such as those with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the company continues to refine and scale its settling technology to support commercial-scale manufacturing and emerging clinical requirements.

AI summary generated on Jun 22, 2026
OpenAlexOpenAlex

For general inquiries

Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.

Looking for

Sponsored researchCo-developmentSupply/purchaseLicensingEquity investmentPilot or trial engagement

Key links

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.